The initiative aims to invest in or acquire small antibiotic companies developing new drugs and therapies. Slated for a formal announcement July 9, the coalition will involve drugmakers such as Eli Lilly, Pfizer, Merck, Boehringer Ingelheim and Bayer.
The venture builds upon the work being done by CARB-X, a public-private partnership formed in 2016 to fund antibiotic development as patients’ need for innovative treatments continues to grow.
More articles on pharmacy:
Cheap steroid in shortage after being posited as potential COVID-19 treatment
Regeneron paid patient charity millions in kickbacks, lawsuit claims
Novartis pays DOJ, SEC $347M in kickback scheme settlement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
